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In the recent decade there is an epidemics-like increase of the number of 
patients with genital herpes (GH) (24). G H presents a serious social-health 
problem in the developed countries. About 200 000—500 000 new cases of the 
disease are yearly registered in the USA (17). G H comes second after gonorrhoe 
(25) according to its frequency but it comes even first amids certain social 
groups (34). The more specific localization and the frequent relapses of the illness 
both have serious consequences for the psychic and sexual patients' activity. G H 
therapy is still an unsolved problem. Recently, there appear some communica-
tions on successful Levamisol application in relapsing herpes simplex (RHS) 
(23, 27). 
The purpose of the present study is the comparison of the therapeutic effect 
of Levamisol alone and its combination with antiherpes vaccine in patients with 
relapsing G H ( R G H ) . 
Material and methods 
A total of 40 patients were administered the Hungarian drug Decaris (Leva-
misol) alone and 35 ones — the combination of Levamisol and antiherpes vaccine 
(second type). The distribution of the patients according to sex and age was as 
followed: 55 males anl 20 females aged between 18 and 60 years. The duration of 
the disease was shorter than one year in 20 paients, between 2 and 5 years in 37, 
and longer than 5 years in 18 ones. Relapses persisted in 21 patients. They ap-
peared once a month in 35 cases and between 5 and 12 times yearly in the rest 
19 ones. Relapse duration was 6—10 days long in 55 patients, more than 10 days 
in 19 ones and shorter than 5 days in one patient only. Relapses tended to become 
more frequent in 36 cases, more seldom in 2 ones while there was no change in the 
rest 37 patients. 
Levamisol was administered thrice daily at one lozenge each (0.050 g) for 
three successive days of the week. Course duration was between 1.5 and 3 months. 
During the treatment after every successive taking of the weekly dosis there was 
a controlling of the haematological indices (erythrocytes, leukocytes and throm-
bocytes). 
Combined treatment (Levamisol+antiherpes vaccine) was performed by 
incorporation of Levamisol after the method described into simultaneous treat-
ment with the vaccine. The antiherpes vaccine was applied s. c. in the following 
way when 20 patients were concerned: 1 s t day — 0.1 ml; 2° 1 day —0.3 ml; 3 r d 
day — 0.5 ml; 4 t h day — 0.7 ml; 5 t h day — 1 ml; 8 t h day — 1 ml; 10 t h day — 
1 ml; and 12 t h day — 1 ml. A total of 6 injections (1 ml each) every 20 days were 
done in the rest 15 patients. 
The effect of the treatment was estimated as followed: very good — lack of 
relapses during observation; good — simultaneous reduction of frequency and 
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severity of relapses; small — influence either on frequency, or on severity of 
relapses, and lack of effect — lack of any influence of treatment. 
Patients were followed-up during the next 2 years after treatment cessation 
in 24 cases, t i l l 4 years — in 23 ones, t i l l 1 only — in 16 ones, and 3 years — in 
1 2 ones. 
Results and discusion 
There was a positive therapeutic effect in 85 per cent of the patients on Le-
vamisol treatment and in 94.3 per cent of those on combined (Levamisol-fan-
tiherpes vaccine) one. It striked that there was a greater percentage of favourable 
influence (71.5) after combined treatment ( i . e. very good — 8.6 per cent and 
good — 62.9 per cent) in comparison with that after Levamisol alone (very 
good — 7.5 per cent and good — 45 per cent) — 52.5 per cent. As a contrary, 
22.8 per cent of the cases with combined treatment and 32.5 per cent of the cases 
with Levamisol one showed a restricted therapeutic effect. The percentage of 
cases free of relapses after combined treatment was almost three times smaller 
(5.7) as compared with that after Levamisol treatment alone (15.0) (see table 1). 
T a b l e 1 
Therapeutic effect of Levamisol alone and of Levamisol -f-antiherpes vaccine in 
recidivans genital herpes patients 
Therapeutic effect 
Therapy applied Patients n 
very good good restricted no effect 
n 1 % n % n % n % 
Levamisol 40 3 7.50 18 45.0 13 32.5 6 15.0 
Levamisol+antiherpes 
vaccine 35 3 8.60 22 62.9 8 22.8 2 5.7 
Reported data available about therapeutic action of Levamisol confirmed 
its positive effect with insignificant exceptions (19,31). Our results obtained were 
similar to these of other investigators. R . Jarisch et al . (22) treated a total of 23 
R H S patients. They achieved an excellent effect in 10 cases, a very good one — 
in 11 while there was no improvement in 2 patients only. C. Luderschmidt and 
H . Wolff (26) reported in a double-blind trial the favourable influence of 
Levamisol upon the frequency and severity of relapses. This drug was success­
fully applied in cases of neonatal herpes, too (13). G. Ganev (4) in Bulgaria and 
some other authors in other countries (21,23) reported also their results from the 
effective therapy with Levamisol. 
According to a series of investigators' (3, 6, 15) data congenital or acquired 
defect of cell-related immunity played an important role in R H S pathogene­
sis. The exact mechanism of Levamisol action was not completely clarified yet. 
In some authors' opinion (36) it enhanced the phagocytic activity of the granulo­
cytes and macrophages and stimulated the cellular immunity in patients with 
reduced Т-lymphocyte activity. 
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Recently, specific vaccine therapy was considered the most effective method 
of prophylaxis and treatment of RHS (8, 9). According to D. Fanta et al. (16) 
it was not perfect but the most optimal method causing a considerable impro­
vement of patients' status. It was assumed that antiherpes vaccines increased 
cell-related immunity (1 , 2). 
We could not find any publications about the combined treatment (Levami-
sol+antiherpes vaccine) of RHS in the literature available. Dundarov and Falke 
(personal communication, 1982) performed similar experiments on mice in GFR. 
However, their results did not excel those after vaccine application only. T. Se-
menova et al. (10) used successfully the combination of antiherpes vaccine and 
interferon inductor. 
We could conclude that our results allowed us to recommend the combina­
tion of Levamisol and antiherpes vaccine as a more effective method for RGH 
treatment than that with Levamisol alone. 
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ЛЕЧЕНИЕ РЕЦИДИВИРУЮЩЕГО ГЕНИТАЛЬНОГО ГЕРПЕСА 
Ш. Томов 
* 
Р Е З Ю М Е 
Проведено лечение 75 больных рецидивирующим генитальньш герпесом: 40 больных 
левамизолом, а остальных 35 — левамизолом в комбинации с противогерпесной вакциной . 
Установлен положительный терапевтический эффект у 85 % больных, лечившихся левами­
золом и 94,3 % больных, лечившихся левамизолом в комбинации с противогерпесноа вак­
циной. Полученные результаты дают основание сделать вывод об ффективности комбинации 
левамизола и противогерпесной вакцины при лечении рецидивирующего генитального гер­
песа, а также рекомендовать этот метод лечения. 
